LEGNLegend Biotech Corporation
Is it safe?
Mostly sound, with a caveat: comfortable debt (AA), but big price swings.
Insiders were net sellers (-$309K, 90 days to Oct 8, 2026), selling is often routine.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -78% · now 49% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can LEGN take a bad year?
Legend Biotech Corporation holds $269M more cash than debt, and is burning $32M a quarter, about 7.0 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 5+ years
Cash runway · burning $32M a quarter at the current rate
- Annualised volatility
- 63%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ4 2025
- $638M
- Cash and short-term investments
- $907M
- Net cash
- $269M
- Debt / equity
- 0.64×
- Annualised volatilitytwo years of daily moves
- 63%
- Worst drawdown on file
- −78%
- Below its 52-week high
- 49%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.